The Aurelius Consulting Group Launches Micro-Cap Newsletter: Highlights CardioTech International and Satcon Technology Corporati

The Aurelius Consulting Group Launches Micro-Cap Newsletter:
Highlights CardioTech International and Satcon Technology Corporation 


WINTER PARK, Fla., July 6  /PRNewswire/ -- The Aurelius Consulting Group, an
internationally recognized investor relations firm, announced today the launch
of a proprietary newsletter, The "Aurelius Micro-Cap Investor"
(http://www.runonideas.com/aureliusinvestor.html).  The newsletter, distributed
electronically and through direct mail, targets Wall Street's micro-cap equity
players, including individual investors, retail stock- brokers, fund-managers
and analysts.

Published bi-monthly, the June/July 2004 issue features two Boston based
companies:  Satcon Technology Corporation (NASDAQ:SATC) and CardioTech
International (AMEX:CTE), both clients of the Aurelius Consulting Group.

The president of the Aurelius Consulting Group, Dave Gentry, stated:  "As
evidenced by our track record and our references (see
http://www.runonideas.com/references.asp;
http://www.runonideas.com/casestudies.asp), we are known for our ability to
attract long-term retail and institutional investors to previously undervalued,
undiscovered companies.  Our newsletter will play an important role in our
comprehensive investor relations awareness programs."

He added, "It is a pleasure to represent companies such as CardioTech
International (CTE), the only company in the world in human clinical trials
with an artificial coronary artery bypass graft, and Satcon Technology
Corporation (SATC), a classic turn-around situation with strong revenue growth
and a leader in the manufacturing and distribution of power conversion systems
for alternative energy technologies."

A spin-off of Polymedica Corporation (PLMD), CardioTech International (CTE) was
founded by Dr. Michael Szycher, one of the inventors of the best- selling
artificial heart, the Heart-Mate. Considered a world authority on polyurethanes
(the material of which the coronary artery bypass graft is made), he has
written five books on the subject and holds 17 patents.  The Company's
potential rocket ship product, the CardioPass, addresses a potential $1.5
billion market.  The Company generated revenues of $21.7 million in fiscal
2004; maintains a strong cash position; is debt free, and is generating
positive cash flow.

The Aurelius network of client companies covers the following sectors: Consumer
Finance, Business Services, Biotech, Medical Device, High-Tech, and Homeland
Defense Semi-conductors and Mining. For a complete list of Aurelius companies
go to: http://www.runonideas.com/.

   For more information Contact:
   Dave Gentry
   Aurelius Consulting Group, Inc.
   225 S. Swoope Ave., Suite 214
   Maitland, Florida 32751
   [phone]
   [phone]
   
   http://www.runonideas.com/



This press release is neither an offer nor solicitation to buy or sell any
securities mentioned. While we believe all sources of information to be factual
and reliable, we have not independently verified all the information contained
herein. We receive compensation to act in an investor relations capacity for
all clients mentioned herein. Also, we, from time to time, receive stock in
compensation for our services from some, but not all of our clients. The large
majority of the stock we receive as compensation is Rule 144 (restricted)
stock, with a holding period of a minimum of 12 months. 

http://www.runonideas.com/aureliusinvestor.html 

                http://www.runonideas.com/references.asp 

                http://www.runonideas.com/casestudies.asp 

DATASOURCE: Aurelius Consulting Group, Inc.



CONTACT:  Dave Gentry, Aurelius Consulting Group, Inc., [phone],

or [phone], or 



Web site:  http://www.runonideas.com/ 

Copyright